News

RadioMedix selected for 2019-2020 NIH SBIR/STTR Commercialization Accelerator Program (CAP)

Posted by RadioMedix . on

RadioMedix selected for 2019-2020 NIH SBIR/STTR Commercialization Accelerator Program (CAP)

Houston, Jan. 02, 2020 (GLOBE NEWSWIRE) — RadioMedix Inc. is pleased to announce that the company has been selected for the 2019-2020 Commercialization Accelerator Program (CAP) by the National Institute of Health (NIH) SBIR/STTR (Small Business Innovation Research/Small Business Technology Transfer) program office. This award is following our two-years, $2.0 M Phase II SBIR funded in part with Federal funds from the National Cancer Institute, National Institutes of Health and Human Services, under Contract No HHSN261201800048C. The Contract focuses on the clinical development of 212Pb-AlphaMedix™ for the targeted alpha-emitter therapy (TAT) of neuroendocrine tumors. ”Selection for this program highlights the value...

Read more →

Novigenix and RadioMedix to Develop Neuroendocrine Cancer Precision Diagnostic Test

Posted by RadioMedix . on

Novigenix and RadioMedix to Develop Neuroendocrine Cancer Precision Diagnostic Test

LAUSANNE, Switzerland–(BUSINESS WIRE)–Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes solutions for early cancer detection and precision medicine, today announced a collaboration agreement with RadioMedix Inc., a radiopharmaceutical company, to develop a precision diagnostic test based on Novigenix’s technology. The test will measure the response in patients with neuroendocrine tumors (NET) treated with Alpha and Beta Peptide Receptor Radionuclide Therapy (PRRT).   “Precise measurement of the therapy response against NET is extremely important for the management of NET patients.” In order to effectively monitor the response following PRRT, Novigenix will develop an immune-transcriptomic based precision diagnostic test using...

Read more →

RadioMedix and Vect-Horus Announce Signing of a Letter of Intent to Co-Develop a Radio-Theranostic Agent for Glioblastoma

Posted by RadioMedix . on

RadioMedix and Vect-Horus Announce Signing of a Letter of Intent to Co-Develop a Radio-Theranostic Agent for Glioblastoma

MARSEILLE, France & HOUSTON–(BUSINESS WIRE)–Vect-Horus and RadioMedix announced today the signing of a Letter of Intent (LOI) to establish an agreement for the co-development of a Vect-Horus theranostic agent for the diagnostic and radiotherapy of Glioblastoma Multiforme (GBM) of the brain. This partnership will marry the expertise of Vect-Horus in targeting tumors with its technology VECTrans® and the know-how of RadioMedix in developing and conducting pre-clinical evaluation and clinical trials with radiopharmaceuticals. GBM is the most common and most aggressive malignant type of primary brain tumors and is a serious and life-threatening condition. The theranostic agent targets the Low-Density Lipoprotein...

Read more →

RadioMedix received $2 M SBIR Phase II Contract award from NCI NIH for the targeted alpha-emitter therapy of neuroendocrine cancers

Posted by RadioMedix . on

RadioMedix received $2 M SBIR Phase II Contract award from NCI NIH for the targeted alpha-emitter therapy of neuroendocrine cancers

Houston, TX (January 21th, 2019) – RadioMedix Inc. is pleased to announce that the company has been awarded a two-year, $2.0 M Phase II SBIR contract award by the NIH NCI (HHSN261201800048C; UPIID:75N91018C00048) for the clinical development of Targeted Alpha-emitter Therapy (TAT) of neuroendocrine tumors. This Phase II Contract award is a continuation of the successfully completed Phase I SBIR contract (HHSN261201600015C). This award will support the Phase I, non-randomized, open-label, dose escalation study to determine the safety, bio-distribution, and preliminary effectiveness of 212Pb-octreotate analog (AlphaMedix™) in adult subjects with Somatostatin Receptor (SSTR) expressing neuroendocrine tumors (NCT03466216). Dr. Izabela Tworowska (RadioMedix) serves...

Read more →

RadioMedix and Curium Announce FDA Fast Track Designation For 64Cu-Dotatate

Posted by RadioMedix . on

RadioMedix and Curium Announce FDA Fast Track Designation For 64Cu-Dotatate

Houston, TX and St. Louis, MO, Jan. 09, 2019 (GLOBE NEWSWIRE) — RadioMedix Inc. and its commercial partner Curium announced today that their investigational diagnostic radiopharmaceutical, 64Cu-Dotatate, was granted Fast Track designation by the U.S. Food and Drug Administration (FDA).  64Cu-Dotatate is a PET diagnostic agent being studied for somatostatin receptor expressing neuroendocrine tumors (NETs).  RadioMedix Inc. has completed the Phase III clinical trial of the agent and expects to file a New Drug Application with the FDA in 2019. “If approved, 64Cu-Dotatate will be an exciting new diagnostic agent for the detection of neuroendocrine tumors,” said Ebrahim Delpassand, MD, CEO of RadioMedix. ...

Read more →